Klin Farmakol Farm. 2012;26(2):79-82

PAR-1, blokátory syntézy tromboxanu A2, antagonisté povrchových destičkových glykoproteinů (GP IIb/IIIa).

Hynek Poul

Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov, p. o.

Antiplatelet therapy

The aim of antiplatelet therapy is the primary and secondary prevention of atherothrombosis which causes serious diseases (acute

coronary syndrome, ischemic stroke, peripheral artery disease) that are among the leading causes of mortality in developed countries.

Acetylsalicylic acid and klopidogrel are considered as the gold standard of antiplatelet therapy with verified benefit. The main drawbacks

of them are treatment failure, individual resistance to the therapy, drug interactions and increased risk of bleeding. A limited efficacy

of classic antiplatelet drugs is observed in some specific groups of patients, for example in patients with type 2 diabetes mellitus or

those with peripheral artery disease. Currently, numerous new antiplatelet drugs are available which inhibit different phases of platelet

thrombus formation. Antiplatelet drugs targeting ADP receptors P2Y, thrombin receptors PAR-1, thromboxane A2 synthesis and IIb/IIIa

glycoprotein receptors have been tested in a large number of clinical trials and some of them are used in clinical practice. But only some

of the new drugs in some specific situations have been shown to be superior to aspirin or klopidogrel. Antiplatelet therapy is always

associated with an increased incidence of bleeding complications.

thromboxane A2 synthesis, IIb/IIIa glycoprotein inhibitors.

Keywords: antiplatelet therapy, atherothrombosis, ADP receptor P2Y inhibitors, PAR-1 thrombin receptor inhibitors, inhibitors of

Published: July 31, 2012  Show citation